Therapeutical Management for Ocular Rosacea by Lopez-Valverde, G. et al.
  
Case Rep Ophthalmol 2016;7:237–242 
10.1159/000446104 
Published online: May 2, 2016 
© 2016 The Author(s) 
Published by S. Karger AG, Basel 
1663-2699/16/0071–0237$39.50/0 
www.karger.com/cop 
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 
International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes requires written permission. 
 
 
           
 
 Gloria López Valverde 
Hospital Nuestra Señora de Gracia 
C/ Ramón y Cajal 60, ES–50004 Zaragoza (Spain) 
E-Mail gloria_lpz@hotmail.com 
 
  
 
 
Therapeutical Management for 
Ocular Rosacea 
Gloria López-Valverdea, b    Elena Garcia-Martinb, c    José Manuel Larrosa-
Povésb, c    Vicente Polo-Llorensb, c    Luis E. Pablo-Júlvezb, c     
a
Hospital Royo Villanova, Zaragoza, Spain; 
b
Hospital Universitario Miguel Servet, 
Zaragoza, Spain; 
c
Instituto de Investigación Sanitaria de Aragón (IIS Aragon), 
Zaragoza, Spain 
Keywords 
Rosacea · Ocular symptoms · Management · Amniotic membrane · Deep anterior lamellar 
keratoplasty 
Abstract 
Purpose: The purpose of this study is to describe a case of ocular rosacea with a very com-
plex evolution. Rosacea is a chronic dermatological disease that may affect the ocular struc-
tures up to 6-72% of all cases. This form is often misdiagnosed, which may lead to long in-
flammatory processes with important visual consequences for affected patients. Therefore, 
an early diagnosis and an adequate treatment are important. Methods: We report the case of 
a 43-year-old patient who had several relapses of what seemed an episode of acute bacterial 
conjunctivitis. Two weeks later, he developed a corneal ulcer with a torpid evolution includ-
ing abundant intrastromal infiltrators and calcium deposits. He was diagnosed with ocular 
rosacea and treated with systemic doxycycline and topical protopic. Results: A coating with 
amniotic membrane was placed in order to heal the ulcer, but a deep anterior lamellar kera-
toplasty to restore the patient’s vision because of the corneal transparency loss was neces-
sary. Conclusions: Ocular rosacea includes multiple ophthalmic manifestations ranging from 
inflammation of the eyelid margin and blepharitis to serious corneal affectations. A delayed 
diagnosis can result in chronic inflammatory conditions including keratinization and loss of 
corneal transparency, which lead to important visual sequelae for affected patients. 
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Introduction 
Rosacea is a chronic skin disease of unknown etiology. It is characterized by the appear-
ance of a persistent erythema, papules, pustules and telangiectasia in varying degrees in the 
forehead skin, cheeks, nose and chin in a symmetrical distribution [1]. Sometimes the lesions 
may appear on extrafacial sites exposed to ultraviolet radiation such as the retro-auricular 
area, sternum, neck or back of the scalp [2]. 
Females are more often affected than males, but the latter show more severe forms such 
as rhinophyma. Disease onset is usually between the third and fifth decades of life, but mani-
festations can occur throughout life course [3, 4]. 
Although the signs are predominantly dermatological, ocular involvement may be pre-
sent in 6–72% of the patients [5]. This entity is often misdiagnosed, which can lead to devas-
tating consequences. 
The main ocular signs include periorbital swelling, eyelid margin erythema and telangi-
ectasia; blepharitis and Meibomian gland affectation; conjunctivochalasis, dry eye and bacte-
rial colonization; erosion, corneal neovascularization and thinning or even perforation [6], 
and episcleritis and scleritis [5, 7]. 
The predominant symptom is ocular blepharoconjunctivitis [8], but up to 33% of the pa-
tients develop corneal injuries that can affect their vision seriously, mainly due to delayed 
diagnosis [9]. The dysfunction of the Meibomian glands can lead to evaporative dry eye syn-
dromes. In fact, some studies have shown increased tear osmolarity and tear dysfunction in 
patients with ocular rosacea [10]. 
The aim of this paper is to present the case of a 43-year-old male with symptoms of ocu-
lar rosacea with a torpid evolution because of the initial diagnostic complexity. 
Case Presentation 
A 43-year-old male came to emergency services after 2 days of pain in his left eye (OS). 
There was no medical history except for right-eye evisceration because of a penetrating 
trauma when he was younger. 
The ophthalmological examination revealed a visual acuity (VA) of 20/20. He presented 
great conjunctival hyperemia with abundant mucous-purulent secretions. The rest of his 
examination appeared to be normal. He was diagnosed with acute bacterial conjunctivitis. 
We recommended washing the eye with saline solution and treatment with topical tobramy-
cin and diclofenac drops every 8 h. 
Five days later, the patient returned due to pain in his OS. Ophthalmic examination was 
unchanged except for the appearance of periorbital erythema in both eyes. No changes to the 
treatment were made. Two days later, he returned because of a clinical worsening. Physical 
examination revealed eyelid margin telangiectasias, eyelid erythema and edema; not only 
great secretions but also conjunctival hyperemia. His ocular motility was normal, and there 
was no change in the rest of the examination. He was diagnosed of preseptal cellulitis, and at 
the insistence of the patient, he was admitted for intravenous antibiotic therapy with amoxi-
cillin-clavulanate 1 g/200 mg every 8 h and ibuprofen 600 mg every 8 h, continuing his topi-
cal treatment. 
The patient was discharged after 5 days. However, given the persistence of ocular nui-
sances and abundant secretions, we performed a culture of the conjunctival exudate, which 
was negative, and he continued with topical antibiotic treatment. 
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Two days after discharge, he returned to emergency with great pain in his OS. His VA 
had decreased to 20/25. The conjunctival hyperemia, amount of secretions and eyelid in-
flammation had not improved, and he had developed a central corneal debridement with 
infiltration. We advised occlusion, cycloplegic every 8 h, and we changed the topical antibi-
otic to moxifloxacin every 4 h and intense lubrication. 
Two days later, the cornea ulcer had central deposits and infiltration, endothelial edema, 
and his VA had fallen to 20/100. The patient was hospitalized, and we started treatment 
with intravenous vancomycin and ceftazidime as well as intravenous corticosteroids, drops 
of ceftazidime and vancomycin alternating every 2 h, cycloplegic every 8 h and artificial tears 
without preservatives profusely. 
We performed a new analysis of conjunctival and corneal exudate cultures, which were 
also negative. Because of the persistence of inflammation and periocular erythema, we con-
sulted with dermatology service, which reached the diagnosis of rosacea and started topical 
tacrolimus (Protopic 0.1%) twice daily on reddened skin. For treating the ocular inflamma-
tion, we developed a preservative-free ointment of tacrolimus 0.02% dissolving prograf 
capsules with vaseline and used it twice daily. We also started systemic treatment with 
doxycycline 100 mg every 12 h for 1 month. 
During the next weeks, the ulcer showed partial closure processes followed by reactiva-
tions (fig. 1). Calcium deposits appeared, and thicker areas with a partial closure of the ulcer 
were observed. 
We decided to perform amniotic membrane transplantation to treat the great inflamma-
tory component and the chronicity of the ulcer using the patch technique. After its reabsorp-
tion 2 weeks later, the keratopathy was completely closed, but a calcium deposit where the 
ulcer was located persisted (fig. 2). 
When the patient’s condition was established, we proposed the possibility of a deep an-
terior lamellar keratoplasty for the removal of the calcareous keratopathy and restoration of 
his corneal transparency (fig. 3). We used oral and ocular corticosteroids to avoid corneal 
rejection, reserving the systemic and topical tacrolimus for the case that new rosacea epi-
sodes appeared. One year after the transplant, the patient is asymptomatic, his VA has im-
proved to 20/30 and the cornea retains its transparency. No other episodes of rosacea reac-
tivation have developed. 
Discussion 
Ocular rosacea is a frequently misdiagnosed entity that can cause severe visual disabili-
ties. Ocular manifestations may precede, follow or occur simultaneously with skin changes, 
but most commonly they develop jointly. The most common ocular signs include blepharitis, 
conjunctival injection, eyelid margin telangiectasias, changes in the Meibomian glands such 
as chalazion or stye or scales and crusts on the eyelids [5, 8, 9]. 
Corneal damages are more severe and can include signs as punctate keratopathy, corne-
al vascularization and corneal thinning and perforation. This involvement is usually bilateral 
but asymmetric. It is common to find limbal vessel dilation associated with rosacea conjunc-
tivitis. Punctate keratitis, subepithelial infiltrates or nodular elevations can be present. 
Sometimes epithelial cysts develop; they can rupture and form ulcers and recurrent corneal 
epithelial erosions very resistant to treatment [10, 11]. Nowadays, the standard treatments 
include eyelid hygiene, oral tetracycline, corticosteroids and lubrication of the ocular sur-
face. 
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Oral doxycycline has been the mainstay of treatment for ocular rosacea but seems to 
provide only moderate benefit and has many side effects, limiting its usage [7, 12]. Systemic 
cyclosporine has been used as an immune suppressant. It inhibits T-lymphocyte activation, 
proliferation and migration as well as cell apoptosis. Oral doxycycline has also been used as 
drops to deal with ocular surface inflammation [7, 12, 13]. Other immunemodulator drugs, 
such as topical tacrolimus, are supposed to have positive effects on ocular rosacea [14], alt-
hough its isolated use was not very effective in our patient. We decided to perform amniotic 
membrane transplantation to control the ocular surface inflammation because the epithelial 
defect persisted in time despite the use of systemic or topical immune suppressors. Some 
authors described the use of amniotic membrane transplantation to control corneal inflam-
mation and avoid neovascularization [15]. In cases where the corneal transparency is in-
volved, corneal transplant may be needed to restore it. 
Nevertheless, ocular treatment alone is not sufficient to alleviate the symptoms so that 
in most cases, it is necessary to treat the skin involvement simultaneously. Treatment dura-
tion is patient-dependent and is intended to control and prevent relapses. 
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Fig. 1. Corneal ulcer with infiltration and endothelial edema. 
 
 
 
Fig. 2. Calcium deposits and partial closure of the ulcer. 
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Fig. 3. State of the cornea after deep anterior lamellar keratoplasty. 
 
